RT Journal Article
SR Electronic
T1 Newborn Antibodies to SARS-CoV-2 detected in cord blood after maternal vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.03.21250579
DO 10.1101/2021.02.03.21250579
A1 Gilbert, Paul
A1 Rudnick, Chad
YR 2021
UL http://medrxiv.org/content/early/2021/02/05/2021.02.03.21250579.abstract
AB Background Maternal vaccination for Influenza and TDaP have been well studied in terms of safety and efficacy for protection of the newborn by placental passage of antibodies. Similar newborn protection would be expected after maternal vaccination against SARS-CoV-2 (the virus responsible for COVID-19). There is a significant and urgent need for research regarding safety and efficacy of vaccination against SARS-CoV-2 during pregnancy. Here, we report the first known case of an infant with SARS-CoV-2 IgG antibodies detectable in cord blood after maternal vaccination.Case presentation A vigorous, healthy, full-term female was born to a COVID-19 naïve mother who had received a single dose of mRNA vaccine for SARS-CoV-2 three weeks prior to delivery. Cord blood antibodies (IgG) were detected to the S-protein of SARS-CoV-2 at time of delivery.Conclusion Here, we report the first known case of an infant with SARS-CoV-2 IgG antibodies detectable in cord blood after maternal vaccination.Competing Interest StatementThe authors have declared no competing interest.Funding Statementno external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Florida Atlantic University Institutional Review Board was consulted and confirmed this case report was exempt from IRB approval under 45 CFR 46.104(d)(4).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesdata referred to in the manuscript is available at request.